Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds
Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren’s therapy. The post Amgen Drug Meets Goals of Key
